---
title: "Lysergide (DT120) in Generalized anxiety disorder: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Clinical presentation - signs and symptoms. Topics: Cognitive symptoms: excessive, uncontrollable worry; Psychological symptoms: restlessness, irritability, and difficulty concentrating; Somatic symptoms: muscle tension, fatigue, and autonomic complaints; Sleep symptoms: difficulty falling or staying asleep, or restless sleep; 1 further topic. 5 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Cognitive symptoms: excessive, uncontrollable worry

> “The disorder is characterized by persistent, excessive, and unrealistic worry about everyday concerns. Worry may involve multiple areas, including finances, family, health, and the future. Excessive worry is difficult to control and is often accompanied by nonspecific psychological and physical symptoms. Excessive worry is the central feature of generalized anxiety disorder.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Clinically, GAD most commonly presents as excessive worry about minor issues, often manifesting with somatic symptoms and pathologic behavioral changes.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Marked, uncontrollable, and anxious worry and fears about everyday events and problems”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.6-2"></a>

### Psychological symptoms: restlessness, irritability, and difficulty concentrating

> “Restlessness or feeling keyed up or on edge.”
> “Difficulty concentrating or mind going blank.”
> “Irritability.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Patients may also describe psychological symptoms, such as excessive nonspecific anxiety and worry, emotional lability, difficulty concentrating, and insomnia.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Anxiety disorders are characterized by disproportionate and constant fear over everyday events accompanied by behavioral and somatic complaints (eg, restlessness, fatigue, problems concentrating, irritability, or sleep problems).”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

<a id="topic-2.2.1.6-3"></a>

### Somatic symptoms: muscle tension, fatigue, and autonomic complaints

> “Being easily fatigued.”
> “Muscle tension.”
> “Patients with anxiety disorders are more likely than those unaffected to also have other chronic medical problems and are twice as likely to present with somatic symptoms.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Patients with anxiety can pose a diagnostic challenge because somatic symptoms are more common than psychological symptoms. Most patients present with vague or nonspecific somatic concerns, including shortness of breath, palpitations, fatigue, headache, dizziness, and restlessness.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Restlessness, fatigue, irritability, difficulty concentrating, muscle tension, sleep disturbance, or autonomic arousal”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “Anxiety disorders are associated with physical symptoms, such as palpitations, shortness of breath, and dizziness.”

Source: [Szuhany and Simon (2022)](https://pubmed.ncbi.nlm.nih.gov/36573969/)

<a id="topic-2.2.1.6-4"></a>

### Sleep symptoms: difficulty falling or staying asleep, or restless sleep

> “Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Complications of generalized anxiety disorder can also lead to, or worsen, other mental and physical conditions, including:”
> “Insomnia”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.6-5"></a>

### Functional impairment: social, occupational, and role functioning

> “The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Respondents with 12-month GAD reported a mean (SE) of 41.2 days (2.4) out of role due to GAD in the past year. Half (50.6%) of the 12-month cases reported severe functional impairment resulting from GAD”
> “The rate of severe impairment was lower yet still substantial (35.3%) among individuals with GAD who had no comorbid disorders”
> “Respondents rated the extent of interference with home management, work, close relationships, and social life on separate 0-to-10 scales.”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

> “Increasing scores on the scale were strongly associated with multiple domains of functional impairment (all 6 Medical Outcomes Study Short-Form General Health Survey scales and disability days).”
> “Moreover, GAD and depression symptoms had differing but independent effects on functional impairment and disability.”

Source: [Spitzer et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16717171/)

> “Disability and impairment in pure GAD were equivalent to pure mood disorders, but significantly greater than in pure substance use, and other anxiety and personality disorders.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

| Generalized anxiety disorder, 12-month cases (NCS-R) | Quoted value, % (se) |
| --- | --- |
| Twelve-month prevalence | “3.1 (0.2)” |
| Serious | “32.3 (2.9)” |
| Moderate | “44.6 (4.0)” |
| Mild | “23.1 (2.9)” |

Source: [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
